{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.05","upperLimit":"0.77","value":"0.20"},{"groupId":"OG001","lowerLimit":"0.09","upperLimit":"1.86","value":"0.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"title":"FOXM1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.07","upperLimit":"0.58","value":"0.20"},{"groupId":"OG001","lowerLimit":"0.01","upperLimit":"0.42","value":"0.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"title":"PTCH1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"description":"Responders were AML participants who achieved CR, CRi, MLFS, PR or PRi based on investigator-reported best overall response and MDS participants who achieved CR, mCR, PR or SD based on investigator-reported best overall response. Whole blood mRNA analyses were performed on 21 mRNA candidates. Baseline mRNA level showing statistically significant correlation with clinical response are reported. FOXM1: Forkhead box M1; PTCH1: Patched 1.","dispersionType":"Full Range","groups":[{"description":"AML subjects who achieved CR, CRi, MLFS, PR, or PRi (AML investigator reported best overall response), and MDS subjects who achieved CR, mCR, PR, or SD (MDS investigator reported best overall response).","id":"OG000","title":"Phase 2 Unfit: Glasdegib 100 mg + LDAC (Biomarker, Responder)"},{"description":"AML subjects who did not achieve CR, CRi, MLFS, PR, or PRi; and MDS subjects who did not achieve CR, mCR, PR or SD were defined as non-responders for best overall response.","id":"OG001","title":"Phase 2 Unfit: Glasdegib 100 mg+LDAC(Biomarker, Non-Responder)"}],"paramType":"MEDIAN","populationDescription":"PD analysis set:all enrolled participants in Phase 2 Unfit who received at least 1 dose of glasdegib, had at least 1 PD parameter with a baseline and an adequate post treatment assessment.","reportingStatus":"POSTED","timeFrame":"Baseline (Cycle 1/Day 1 pre-dose)","title":"Baseline mRNA Levels Associated With Best Overall Response at Phase 2 Unfit","type":"SECONDARY","unitOfMeasure":"Normalized expression units"}